5 completed, 1 recruiting, 1 unknown. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Multiple Sclerosis, Secondary Progressive: new trials by email Literature Review of Multiple Sclerosis, Secondary Progressive trials Research Report on Multiple Sclerosis, Secondary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF PIPE-791 - Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Contineum Therapeutics | 16 | 2024-12-09 | 2025-08-06 |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 1 | Recruiting | Stanford University | 12 | 2024-04-10 | 2026-02-27 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Extracorporeal Photopheresis, MS standard of care - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Completed | Abu Dhabi Stem Cells Center | 15 | 2022-03-26 | 2026-05-07 |
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Insulin, Placebo (Sterile diluent) - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 105 | 2017-12-01 | 2023-03-10 |
| Open-label Study of Liothyronine in MS liothyronine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 | Completed | Johns Hopkins University | 20 | 2015-07-01 | 2018-02-12 |
| Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Andrographolides, placebo - Primary Progressive Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Unknown | Innobioscience SpA | 68 | 2014-09-01 | 2014-10-27 |
| Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis Tovaxin Autologous T Cell Vaccine - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Opexa Therapeutics, Inc. | 16 | 2002-07-01 | 2017-01-11 |
Multiple Sclerosis, Chronic Progressive (7) · Multiple Sclerosis, Relapsing-Remitting (4) · Multiple Sclerosis (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Idiopathic Pulmonary Fibrosis (1) · Immune System Diseases (1) · Nervous System Diseases (1) · Neuroinflammatory Diseases (1) · Pathologic Processes (1) · Sclerosis (1)
Chronic Disease (7) · Disease Attributes (7) · Pathological Conditions, Signs and Symptoms (7) · Autoimmune Diseases of the Nervous System (6) · Demyelinating Autoimmune Diseases, CNS (6) · Demyelinating Diseases (6) · Immune System Diseases (6) · Nervous System Diseases (6) · Pathologic Processes (6) · Autoimmune Diseases (5) · Multiple Sclerosis (4) · Brain Diseases (1) · Central Nervous System Diseases (1) · Inflammation (1) · Leukoencephalopathies (1)
Bendamustine Hydrochloride (1) · Insulin (1) · Photochemotherapy (1) · Photopheresis (1) · Triiodothyronine (1) · andrographolide (1) · neoandrographolide (1)
Johns Hopkins University (2) · Abu Dhabi Stem Cells Center (1) · Contineum Therapeutics (1) · Innobioscience SpA (1) · Opexa Therapeutics, Inc. (1) · Stanford University (1)
United States (4) · Chile (1) · United Arab Emirates (1) · United Kingdom (1)
Scott Newsome, DO (2) · Ellen Mowry, MD, MCR (1) · Jaye Thompson, PhD (1) · Jeffrey Dunn, MD (1) · Juan L Hancke, DVM, PhD (1) · Stephen Huhn, MD (1) · Yendry Ventura Carmenate, M.D. (1)